EA201891286A1 - АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Info

Publication number
EA201891286A1
EA201891286A1 EA201891286A EA201891286A EA201891286A1 EA 201891286 A1 EA201891286 A1 EA 201891286A1 EA 201891286 A EA201891286 A EA 201891286A EA 201891286 A EA201891286 A EA 201891286A EA 201891286 A1 EA201891286 A1 EA 201891286A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
application
antibodies
amyloid peptide
beta amyloid
Prior art date
Application number
EA201891286A
Other languages
English (en)
Other versions
EA037784B1 (ru
Inventor
Рональд Брэдли Дематтос
Цзижун Лу
Ин Тан
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201891286A1 publication Critical patent/EA201891286A1/ru
Publication of EA037784B1 publication Critical patent/EA037784B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Антитела к N3pGlu Aβ человека, композиции, содержащие такие антитела к N3pGlu Аβ, и способы применения таких антител к N3pGlu Aβ для лечения болезни, характеризующейся отложением Aβ, включая клиническую или доклиническую болезнь Альцгеймера, синдром Дауна, и клиническую или доклиническую церебральную амилоидную ангиопатию.
EA201891286A 2016-01-15 2017-01-10 АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ EA037784B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662279268P 2016-01-15 2016-01-15
PCT/US2017/012795 WO2017123517A1 (en) 2016-01-15 2017-01-10 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Publications (2)

Publication Number Publication Date
EA201891286A1 true EA201891286A1 (ru) 2018-12-28
EA037784B1 EA037784B1 (ru) 2021-05-20

Family

ID=57966094

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891286A EA037784B1 (ru) 2016-01-15 2017-01-10 АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Country Status (17)

Country Link
US (1) US9944696B2 (ru)
EP (1) EP3402817B1 (ru)
JP (1) JP6634158B2 (ru)
KR (1) KR102141969B1 (ru)
CN (2) CN114891100B (ru)
AR (1) AR107290A1 (ru)
AU (1) AU2017207250B2 (ru)
BR (1) BR112018011308A2 (ru)
CA (1) CA3007000C (ru)
EA (1) EA037784B1 (ru)
ES (1) ES2968255T3 (ru)
IL (1) IL259748B2 (ru)
JO (1) JOP20170004B1 (ru)
MX (1) MX2018008557A (ru)
TW (1) TWI634126B (ru)
WO (1) WO2017123517A1 (ru)
ZA (1) ZA201901207B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
EP3755335A4 (en) 2018-02-14 2022-06-22 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES
EP3752156A4 (en) 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC PRALATREXATE GAMMA-POLYGLUTAMATE AND ASSOCIATED USES
US20220177560A1 (en) 2019-03-26 2022-06-09 Janssen Pharmaceutica Nv Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
TW202216760A (zh) 2020-07-23 2022-05-01 愛爾蘭商歐薩爾普羅席納有限公司 抗類澱粉β (ABETA)抗體
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
MX2024005145A (es) 2021-10-29 2024-05-13 Lilly Co Eli Compuestos y metodos dirigidos a la interleucina-34.
TW202336034A (zh) 2021-10-29 2023-09-16 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
WO2023077042A1 (en) 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
MX2024005146A (es) 2021-10-29 2024-05-13 Lilly Co Eli Compuestos y metodos dirigidos a interleucina-34.
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
WO2024133925A1 (en) 2022-12-22 2024-06-27 Bioarctic Ab Antibody which binds to abetape3
CN118459583B (zh) * 2024-07-11 2024-09-10 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
JP5042828B2 (ja) 2004-07-30 2012-10-03 ライナット ニューロサイエンス コーポレイション アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US20110092436A1 (en) 2008-06-12 2011-04-21 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
US20110182809A1 (en) 2008-07-09 2011-07-28 University Of Zurich Method of Promoting Neurogenesis
CN102131519B (zh) * 2008-07-21 2016-01-13 前体生物药物股份公司 诊断抗体测定
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
AU2014233615B2 (en) * 2010-08-12 2016-08-11 Eli Lilly And Company Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof
BR112013004056B8 (pt) * 2010-08-12 2022-10-18 Lilly Co Eli Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples

Also Published As

Publication number Publication date
JOP20170004B1 (ar) 2022-09-15
EA037784B1 (ru) 2021-05-20
ES2968255T3 (es) 2024-05-08
CA3007000A1 (en) 2017-07-20
WO2017123517A1 (en) 2017-07-20
MX2018008557A (es) 2018-09-18
EP3402817A1 (en) 2018-11-21
EP3402817B1 (en) 2023-10-18
CN108473566A (zh) 2018-08-31
JP6634158B2 (ja) 2020-01-22
IL259748B2 (en) 2023-03-01
AU2017207250A1 (en) 2018-06-07
CN108473566B (zh) 2022-06-17
BR112018011308A2 (pt) 2018-11-27
CA3007000C (en) 2021-07-27
US20170204171A1 (en) 2017-07-20
CN114891100A (zh) 2022-08-12
AU2017207250B2 (en) 2019-04-18
KR102141969B1 (ko) 2020-08-06
JP2019507107A (ja) 2019-03-14
IL259748A (en) 2018-07-31
US9944696B2 (en) 2018-04-17
TW201739761A (zh) 2017-11-16
KR20180086268A (ko) 2018-07-30
AR107290A1 (es) 2018-04-18
ZA201901207B (en) 2022-05-25
IL259748B (en) 2022-11-01
CN114891100B (zh) 2024-05-03
TWI634126B (zh) 2018-09-01

Similar Documents

Publication Publication Date Title
EA201891286A1 (ru) АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201992163A1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201791590A1 (ru) Антитела к tau и их применение
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
EA201892690A1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EA201990400A1 (ru) Соединения и композиции и их применение
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA202190094A1 (ru) Антитела против cd40 для применения в лечении аутоиммунного заболевания
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
EA201990559A1 (ru) Комбинированная терапия
FR3052669B1 (fr) Prothese biologique destinee au traitement des hernies parastomales